array(4) {
  ["posts_per_page"]=>
  string(1) "5"
  ["cat"]=>
  int(2690)
  ["p"]=>
  string(0) ""
  ["suppress_filters"]=>
  int(0)
}
array(6) {
  ["posts_per_page"]=>
  string(1) "5"
  ["cat"]=>
  int(2690)
  ["p"]=>
  string(0) ""
  ["suppress_filters"]=>
  int(0)
  ["paged"]=>
  int(3)
  ["meta_query"]=>
  array(1) {
    [0]=>
    array(0) {
    }
  }
}
object(WP_Query)#18179 (57) {
  ["query"]=>
  array(6) {
    ["posts_per_page"]=>
    string(1) "5"
    ["cat"]=>
    int(2690)
    ["p"]=>
    string(0) ""
    ["suppress_filters"]=>
    int(0)
    ["paged"]=>
    int(3)
    ["meta_query"]=>
    array(1) {
      [0]=>
      array(0) {
      }
    }
  }
  ["query_vars"]=>
  array(64) {
    ["posts_per_page"]=>
    int(5)
    ["cat"]=>
    int(2690)
    ["p"]=>
    int(0)
    ["suppress_filters"]=>
    int(0)
    ["paged"]=>
    int(3)
    ["meta_query"]=>
    array(1) {
      [0]=>
      array(0) {
      }
    }
    ["error"]=>
    string(0) ""
    ["m"]=>
    string(0) ""
    ["post_parent"]=>
    string(0) ""
    ["subpost"]=>
    string(0) ""
    ["subpost_id"]=>
    string(0) ""
    ["attachment"]=>
    string(0) ""
    ["attachment_id"]=>
    int(0)
    ["name"]=>
    string(0) ""
    ["pagename"]=>
    string(0) ""
    ["page_id"]=>
    int(0)
    ["second"]=>
    string(0) ""
    ["minute"]=>
    string(0) ""
    ["hour"]=>
    string(0) ""
    ["day"]=>
    int(0)
    ["monthnum"]=>
    int(0)
    ["year"]=>
    int(0)
    ["w"]=>
    int(0)
    ["category_name"]=>
    string(12) "publications"
    ["tag"]=>
    string(0) ""
    ["tag_id"]=>
    string(0) ""
    ["author"]=>
    string(0) ""
    ["author_name"]=>
    string(0) ""
    ["feed"]=>
    string(0) ""
    ["tb"]=>
    string(0) ""
    ["meta_key"]=>
    string(0) ""
    ["meta_value"]=>
    string(0) ""
    ["preview"]=>
    string(0) ""
    ["s"]=>
    string(0) ""
    ["sentence"]=>
    string(0) ""
    ["title"]=>
    string(0) ""
    ["fields"]=>
    string(0) ""
    ["menu_order"]=>
    string(0) ""
    ["embed"]=>
    string(0) ""
    ["category__in"]=>
    array(0) {
    }
    ["category__not_in"]=>
    array(0) {
    }
    ["category__and"]=>
    array(0) {
    }
    ["post__in"]=>
    array(0) {
    }
    ["post__not_in"]=>
    array(0) {
    }
    ["post_name__in"]=>
    array(0) {
    }
    ["tag__in"]=>
    array(0) {
    }
    ["tag__not_in"]=>
    array(0) {
    }
    ["tag__and"]=>
    array(0) {
    }
    ["tag_slug__in"]=>
    array(0) {
    }
    ["tag_slug__and"]=>
    array(0) {
    }
    ["post_parent__in"]=>
    array(0) {
    }
    ["post_parent__not_in"]=>
    array(0) {
    }
    ["author__in"]=>
    array(0) {
    }
    ["author__not_in"]=>
    array(0) {
    }
    ["ignore_sticky_posts"]=>
    bool(false)
    ["cache_results"]=>
    bool(true)
    ["update_post_term_cache"]=>
    bool(true)
    ["lazy_load_term_meta"]=>
    bool(true)
    ["update_post_meta_cache"]=>
    bool(true)
    ["post_type"]=>
    string(0) ""
    ["nopaging"]=>
    bool(false)
    ["comments_per_page"]=>
    string(2) "50"
    ["no_found_rows"]=>
    bool(false)
    ["order"]=>
    string(4) "DESC"
  }
  ["tax_query"]=>
  object(WP_Tax_Query)#18495 (6) {
    ["queries"]=>
    array(1) {
      [0]=>
      array(5) {
        ["taxonomy"]=>
        string(8) "category"
        ["terms"]=>
        array(1) {
          [0]=>
          int(2690)
        }
        ["field"]=>
        string(7) "term_id"
        ["operator"]=>
        string(2) "IN"
        ["include_children"]=>
        bool(true)
      }
    }
    ["relation"]=>
    string(3) "AND"
    ["table_aliases":protected]=>
    array(1) {
      [0]=>
      string(21) "wp_term_relationships"
    }
    ["queried_terms"]=>
    array(1) {
      ["category"]=>
      array(2) {
        ["terms"]=>
        array(1) {
          [0]=>
          int(2690)
        }
        ["field"]=>
        string(7) "term_id"
      }
    }
    ["primary_table"]=>
    string(8) "wp_posts"
    ["primary_id_column"]=>
    string(2) "ID"
  }
  ["meta_query"]=>
  object(WP_Meta_Query)#18494 (9) {
    ["queries"]=>
    array(0) {
    }
    ["relation"]=>
    string(3) "AND"
    ["meta_table"]=>
    NULL
    ["meta_id_column"]=>
    NULL
    ["primary_table"]=>
    NULL
    ["primary_id_column"]=>
    NULL
    ["table_aliases":protected]=>
    array(0) {
    }
    ["clauses":protected]=>
    array(0) {
    }
    ["has_or_relation":protected]=>
    bool(false)
  }
  ["date_query"]=>
  bool(false)
  ["request"]=>
  string(1319) "SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID FROM wp_posts  LEFT JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id) JOIN wp_icl_translations wpml_translations
							ON wp_posts.ID = wpml_translations.element_id
								AND wpml_translations.element_type = CONCAT('post_', wp_posts.post_type)  WHERE 1=1  AND ( 
  wp_term_relationships.term_taxonomy_id IN (2690)
) AND wp_posts.post_type = 'post' AND (wp_posts.post_status = 'publish' OR wp_posts.post_status = 'acf-disabled' OR wp_posts.post_status = 'tribe-ea-success' OR wp_posts.post_status = 'tribe-ea-failed' OR wp_posts.post_status = 'tribe-ea-schedule' OR wp_posts.post_status = 'tribe-ea-pending' OR wp_posts.post_status = 'tribe-ea-draft') AND ( ( ( wpml_translations.language_code = 'en' OR 0 ) AND wp_posts.post_type  IN ('post','page','attachment','wp_block','accordions','dt_portfolio','dt_gallery','dt_team','dt_testimonials','dt_slideshow','tp_accordions_pro','wp-timeline','tribe_venue','tribe_organizer','tribe_events' )  ) OR wp_posts.post_type  NOT  IN ('post','page','attachment','wp_block','accordions','dt_portfolio','dt_gallery','dt_team','dt_testimonials','dt_slideshow','tp_accordions_pro','wp-timeline','tribe_venue','tribe_organizer','tribe_events' )  ) GROUP BY wp_posts.ID ORDER BY wp_posts.post_date DESC LIMIT 10, 5"
  ["posts"]=>
  array(5) {
    [0]=>
    object(WP_Post)#18556 (24) {
      ["ID"]=>
      int(26962)
      ["post_author"]=>
      string(1) "1"
      ["post_date"]=>
      string(19) "2016-01-11 10:22:00"
      ["post_date_gmt"]=>
      string(19) "2016-01-11 10:22:00"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(136) "Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases"
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(135) "combination-of-cisplatin-and-lurbinectedin-as-palliative-chemotherapy-in-progressive-malignant-pleural-mesothelioma-report-of-two-cases"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2019-02-25 17:35:00"
      ["post_modified_gmt"]=>
      string(19) "2019-02-25 17:35:00"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(181) "http://pharmamar-cp446.wordpresstemporal.com/combination-of-cisplatin-and-lurbinectedin-as-palliative-chemotherapy-in-progressive-malignant-pleural-mesothelioma-report-of-two-cases/"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
    [1]=>
    object(WP_Post)#18496 (24) {
      ["ID"]=>
      int(26959)
      ["post_author"]=>
      string(1) "1"
      ["post_date"]=>
      string(19) "2016-01-11 10:20:21"
      ["post_date_gmt"]=>
      string(19) "2016-01-11 10:20:21"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(156) "Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary"
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(154) "preclinical-investigations-of-pm01183-lurbinectedin-as-a-single-agent-or-in-combination-with-other-anticancer-agents-for-clear-cell-carcinoma-of-the-ovary"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2019-02-25 17:33:52"
      ["post_modified_gmt"]=>
      string(19) "2019-02-25 17:33:52"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(200) "http://pharmamar-cp446.wordpresstemporal.com/preclinical-investigations-of-pm01183-lurbinectedin-as-a-single-agent-or-in-combination-with-other-anticancer-agents-for-clear-cell-carcinoma-of-the-ovary/"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
    [2]=>
    object(WP_Post)#44851 (24) {
      ["ID"]=>
      int(26956)
      ["post_author"]=>
      string(1) "1"
      ["post_date"]=>
      string(19) "2016-01-11 10:18:36"
      ["post_date_gmt"]=>
      string(19) "2016-01-11 10:18:36"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(209) "Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM01183 (lurbinectedin), a novel antineoplastic agent, in mouse, rat, dog, Cynomolgus monkey and mini-pig plasma."
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(192) "development-of-a-liquid-chromatographytandem-mass-spectrometry-assay-for-the-quantification-of-pm01183-lurbinectedin-a-novel-antineoplastic-agent-in-mouse-rat-dog-cynomolgus-monkey-and-mini-pi"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2019-02-25 17:34:29"
      ["post_modified_gmt"]=>
      string(19) "2019-02-25 17:34:29"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(238) "http://pharmamar-cp446.wordpresstemporal.com/development-of-a-liquid-chromatographytandem-mass-spectrometry-assay-for-the-quantification-of-pm01183-lurbinectedin-a-novel-antineoplastic-agent-in-mouse-rat-dog-cynomolgus-monkey-and-mini-pi/"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
    [3]=>
    object(WP_Post)#44852 (24) {
      ["ID"]=>
      int(26953)
      ["post_author"]=>
      string(1) "1"
      ["post_date"]=>
      string(19) "2016-01-11 10:15:01"
      ["post_date_gmt"]=>
      string(19) "2016-01-11 10:15:01"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(154) "Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 (lurbinectedin) in combiantion with olaparib in patients with advanced solid tumors"
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(151) "phase-ibii-study-to-evaluate-the-efficacy-and-tolerability-of-pm01183-lurbinectedin-in-combiantion-with-olaparib-in-patients-with-advanced-solid-tumors"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2019-02-25 17:34:32"
      ["post_modified_gmt"]=>
      string(19) "2019-02-25 17:34:32"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(197) "http://pharmamar-cp446.wordpresstemporal.com/phase-ibii-study-to-evaluate-the-efficacy-and-tolerability-of-pm01183-lurbinectedin-in-combiantion-with-olaparib-in-patients-with-advanced-solid-tumors/"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
    [4]=>
    object(WP_Post)#18499 (24) {
      ["ID"]=>
      int(26947)
      ["post_author"]=>
      string(1) "1"
      ["post_date"]=>
      string(19) "2016-01-11 10:10:12"
      ["post_date_gmt"]=>
      string(19) "2016-01-11 10:10:12"
      ["post_content"]=>
      string(0) ""
      ["post_title"]=>
      string(177) "Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion esults with or withut the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors"
      ["post_excerpt"]=>
      string(0) ""
      ["post_status"]=>
      string(7) "publish"
      ["comment_status"]=>
      string(6) "closed"
      ["ping_status"]=>
      string(6) "closed"
      ["post_password"]=>
      string(0) ""
      ["post_name"]=>
      string(167) "lurbinectedin-pm01183-plus-paclitaxel-p-recommended-dose-rd-expansion-results-with-or-withut-the-addition-of-bevacizumab-bev-in-patients-pts-with-selected-solid-tumors"
      ["to_ping"]=>
      string(0) ""
      ["pinged"]=>
      string(0) ""
      ["post_modified"]=>
      string(19) "2019-02-25 17:34:35"
      ["post_modified_gmt"]=>
      string(19) "2019-02-25 17:34:35"
      ["post_content_filtered"]=>
      string(0) ""
      ["post_parent"]=>
      int(0)
      ["guid"]=>
      string(213) "http://pharmamar-cp446.wordpresstemporal.com/lurbinectedin-pm01183-plus-paclitaxel-p-recommended-dose-rd-expansion-results-with-or-withut-the-addition-of-bevacizumab-bev-in-patients-pts-with-selected-solid-tumors/"
      ["menu_order"]=>
      int(0)
      ["post_type"]=>
      string(4) "post"
      ["post_mime_type"]=>
      string(0) ""
      ["comment_count"]=>
      string(1) "0"
      ["filter"]=>
      string(3) "raw"
    }
  }
  ["post_count"]=>
  int(5)
  ["current_post"]=>
  int(-1)
  ["in_the_loop"]=>
  bool(false)
  ["post"]=>
  object(WP_Post)#18556 (24) {
    ["ID"]=>
    int(26962)
    ["post_author"]=>
    string(1) "1"
    ["post_date"]=>
    string(19) "2016-01-11 10:22:00"
    ["post_date_gmt"]=>
    string(19) "2016-01-11 10:22:00"
    ["post_content"]=>
    string(0) ""
    ["post_title"]=>
    string(136) "Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases"
    ["post_excerpt"]=>
    string(0) ""
    ["post_status"]=>
    string(7) "publish"
    ["comment_status"]=>
    string(6) "closed"
    ["ping_status"]=>
    string(6) "closed"
    ["post_password"]=>
    string(0) ""
    ["post_name"]=>
    string(135) "combination-of-cisplatin-and-lurbinectedin-as-palliative-chemotherapy-in-progressive-malignant-pleural-mesothelioma-report-of-two-cases"
    ["to_ping"]=>
    string(0) ""
    ["pinged"]=>
    string(0) ""
    ["post_modified"]=>
    string(19) "2019-02-25 17:35:00"
    ["post_modified_gmt"]=>
    string(19) "2019-02-25 17:35:00"
    ["post_content_filtered"]=>
    string(0) ""
    ["post_parent"]=>
    int(0)
    ["guid"]=>
    string(181) "http://pharmamar-cp446.wordpresstemporal.com/combination-of-cisplatin-and-lurbinectedin-as-palliative-chemotherapy-in-progressive-malignant-pleural-mesothelioma-report-of-two-cases/"
    ["menu_order"]=>
    int(0)
    ["post_type"]=>
    string(4) "post"
    ["post_mime_type"]=>
    string(0) ""
    ["comment_count"]=>
    string(1) "0"
    ["filter"]=>
    string(3) "raw"
  }
  ["comment_count"]=>
  int(0)
  ["current_comment"]=>
  int(-1)
  ["found_posts"]=>
  string(2) "63"
  ["max_num_pages"]=>
  float(13)
  ["max_num_comment_pages"]=>
  int(0)
  ["is_single"]=>
  bool(false)
  ["is_preview"]=>
  bool(false)
  ["is_page"]=>
  bool(false)
  ["is_archive"]=>
  bool(true)
  ["is_date"]=>
  bool(false)
  ["is_year"]=>
  bool(false)
  ["is_month"]=>
  bool(false)
  ["is_day"]=>
  bool(false)
  ["is_time"]=>
  bool(false)
  ["is_author"]=>
  bool(false)
  ["is_category"]=>
  bool(true)
  ["is_tag"]=>
  bool(false)
  ["is_tax"]=>
  bool(false)
  ["is_search"]=>
  bool(false)
  ["is_feed"]=>
  bool(false)
  ["is_comment_feed"]=>
  bool(false)
  ["is_trackback"]=>
  bool(false)
  ["is_home"]=>
  bool(false)
  ["is_privacy_policy"]=>
  bool(false)
  ["is_404"]=>
  bool(false)
  ["is_embed"]=>
  bool(false)
  ["is_paged"]=>
  bool(true)
  ["is_admin"]=>
  bool(false)
  ["is_attachment"]=>
  bool(false)
  ["is_singular"]=>
  bool(false)
  ["is_robots"]=>
  bool(false)
  ["is_posts_page"]=>
  bool(false)
  ["is_post_type_archive"]=>
  bool(false)
  ["query_vars_hash":"WP_Query":private]=>
  string(32) "7a09c9b020529569d4e8a05b5b75325a"
  ["query_vars_changed":"WP_Query":private]=>
  bool(false)
  ["thumbnails_cached"]=>
  bool(false)
  ["stopwords":"WP_Query":private]=>
  NULL
  ["compat_fields":"WP_Query":private]=>
  array(2) {
    [0]=>
    string(15) "query_vars_hash"
    [1]=>
    string(18) "query_vars_changed"
  }
  ["compat_methods":"WP_Query":private]=>
  array(2) {
    [0]=>
    string(16) "init_query_flags"
    [1]=>
    string(15) "parse_tax_query"
  }
  ["tribe_is_event"]=>
  bool(false)
  ["tribe_is_multi_posttype"]=>
  bool(false)
  ["tribe_is_event_category"]=>
  bool(false)
  ["tribe_is_event_venue"]=>
  bool(false)
  ["tribe_is_event_organizer"]=>
  bool(false)
  ["tribe_is_event_query"]=>
  bool(false)
  ["tribe_is_past"]=>
  bool(false)
}

Publication: Lung Cancer

Year: 2016

Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases

Authors:
Metaxas, Y.; Cathomas, R.; Mark, M.; von Moos, R.

Publication: Plos One

Year: 2016

Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary

Authors:
Takahashi, R.; Mabuchi, S.; Kawano, M.; Sasano, T.; Matsumoto, Y.; Kuroda, H.; Kozasa, K.; Hashimoto, K.; Sawada, K.; Kimura, T.

Publication: Eur J Cancer

Year: 2016

Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 (lurbinectedin) in combiantion with olaparib in patients with advanced solid tumors

Authors:
Poveda, A.M.; Oaknin, A.; Romero, I.; Guerrero, A.; Fariñas Madrid, L.; Soto, A.; Peris, C.; L. Guerrero, J.A.

Publication: Eur J Cancer

Year: 2016

Lurbinectedin (PM01183) plus paclitaxel (P), recommended dose (RD) expansion esults with or withut the addition of bevacizumab (Bev) in patients (pts) with selected solid tumors

Authors:
Drilon, A.; Garralda, E.; Stathis, A.; Szyldergemajn, S.; Hyman, D.; Boni, V.; Griguolo, G.; Jimenez Martinez, E.; Makker, V.; Canziani, L.; Fernández Teruel, C.; Soto-Matos, A.; Sessa, C.; Calvo, E.